In an article in the Dec. 8, 1994 BioWorld Today about TriGenixInc., a private contract sales and marketing company that recentlyclosed its doors, certain language used implied that TriGenix hadsigned a contract with Quadra Logic Technologies Inc., ofVancouver, Canada, to market that firm's drug, Photofrin. In fact, afinal agreement between the two companies was never signed,according to David Main, Quadra Logic's director of corporatecommunications. Main said that his firm decided "after duediligence" that TriGenix "did not have the financial stability tolaunch a product for us."
(c) 1997 American Health Consultants. All rights reserved.